Institute Jules Bordet
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
Institute Jules Bordet
Jun 20, 2024, 11:58 |
Insight
Elisa Agostinetto: A must-read for all oncologists
Elisa Agostinetto recently shared a post on X: "Published in 2023 and yet addressing a…
May 19, 2024, 14:11 |
Societies
20 Posts Not To Miss From ESMOBreast24!
ESMO Breast Cancer 2024 (ESMOBreast24) took place as an onsite and online event in Berlin,…
May 19, 2024, 13:38 |
Insight
Elisa Agostinetto: I discussed the results of our work with Video Journal of Oncology at ESMOBreast24
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: “At…
May 17, 2024, 15:08 |
Societies
Elisa Agostinetto: our poster exploring histologic subtypes of early breast cancers at ESMOBreast24
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on X: "At ESMOBreast24, we…
May 7, 2024, 06:28 |
Insight
Elisa Agostinetto: The long and winding road to biomarkers for immunotherapy
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared on LinkedIn: "The long and…
All:
5
Posts:
1 - 10
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Yardena Samuels: An absolute honor to be elected as the next EACR president
Facebook
RSS Feed
Twitter
Linkedin
Youtube